Treatment of Subacute Sclerosing Panencephalitis With Interferon-α,Ribavirin,and Inosiplex

Abstract

Subacute sclerosing panencephalitis is an almost universally fatal late complication of measles infection for which there is no established treatment. We report a patient with subacute sclerosing panencephalitis who was bed-bound and ataxic and had a left hemiparesis and frequent myoclonus. He was started on a new regimen consisting of intraventricular interferon-α (starting at 100,000 U/m²/day, building up to 1 million U/m²/day), ribavirin (60 mg/kg/day intravenously), and inosiplex (3 g/day) and improved markedly. At 10 weeks, the intraventricular reservoir was removed because of bacterial infection, and he was discharged home on oral ribavirin (1200 mg/kg/day) and inosiplex. He continued to improve as judged by neurologic examination, functional independence measurement, neuropsychometry and single photon emission computed tomography (SPECT) imaging. However, after 10 months, he deteriorated suddenly and died before further intraventricular treatment could be instituted. Further trials are needed to evaluate long-term combination therapy in subacute sclerosing panencephalitis. (J Child Neurol 2002;17:703-705).

Get full access to this article

View all access options for this article.

References

Gascon G. , Yamani S. , Crowell J. , et al: Combined oral isoprinosine-intraventricular alpha-interferon therapy for subacute sclerosing panencephalitis. Brain Dev 1993; 15:346-355.

Fayad MN , Yamout BI , Mroueh S. : Alpha interferon in the treatment of subacute sclerosing panencephalitis. J Child Neurol 1997; 12:486-488.

Houff SA : Subacute sclerosing panencephalitis, in Gilman S , Goldstein GW , Waxman SG (eds): Neurobase, 1st 2001 ed. San Diego, Medlink Publishing, 2001 .

Maimone D. , Grimaldi LM , Incorpora G. , et al: Intrathecal interferon in subacute sclerosing panencephalitis . Acta Neurol Scand 1988;78:161-166.

Honda Y. , Hosoya M. , Ishii T. , et al: Effect of ribavirin on subacute sclerosing panencephalitis virus infection in hamsters. Antimicrob Agents Chemother 1994;38:653-655.

Ogle JW , Parker WD , Alvarez N. , et al: Oral ribavirin therapy for subacute sclerosing panencephalitis . J Infect Dis 1989;159:748-750.

Tomoda A. , Shiraishi S. , Hosoya M. , et al: Combined treatment with interferon-alpha and ribavirin for subacute sclerosing panencephalitis. Pediatr Neurol 2001;24:54-59.

Jabbour JT , Garcia JH , Lemmi H. , et al: Subacute sclerosing panencephalitis: Multidisciplinary study of eight cases. JAMA 1969;207:2248-2254.

Branger CV , Hamilton BB , Keith RA , Sherwin FS : Advances in functional assessment for medical rehabilitation. Top Geriatr Rehabil 1986;1:59-74.

10.

Zilber N. , Kahana E. : Environmental risk factors for subacute sclerosing panencephalitis (SSPE) . Acta Neurol Scand 1998;98:49-54.

11.

Gascon GG : Subacute sclerosing panencephalitis. Semin Pediatr Neurol 1996;3:260-269.

12.

Dlugos DJ , Liu GT : Subacute sclerosing panencephalitis in an American-bom adult. Clin Infect Dis 2001;32:173-174.

13.

Elliman D. , Bedford H. : MMR vaccine: The continuing saga. BMJ 2001 ;322:183-184.

14.

Baczku K. , Liebert UG , Billeter M. , et al: Expression of defective measles virus genes in brain tissue of patients with subacute sclerosing panencephalitis. J Virol 1986;59:472-478.

15.

Anlar B. , Soylemezoglu F. , Aysun S. , et al: Tissue inflammatory response in subacute sclerosing panencephalitis (SSPE). J Child Neurol 2001;16:895-900.

16.

Yalaz K. , Anlar B. , Oktem F. , et al: Intraventricular interferon and oral inosiplex in the treatment of subacute sclerosing panencephalitis. Neurology 1992;42:488-491.

17.

Murphy MF : In vitro inhibition of subacute sclerosing panencephalitis virus by the antiviral agent ribavirin. J Infect Dis 1978;138:249-251.

18.

Takahashi T. , Hosoya M. , Kimura K. , et al: The cooperative effect of interferon alpha and ribavirin on subacute sclerosing panencephalitis (SSPE) virus infections, in vitro and in vivo. Antiviral Res 1998;37:29-35.

19.

Banks G. , Fernandez H. : Clinical use of ribavirin in measles: A summarized review, in Smith RA , Knight V , Smith JAD (eds): Clinical Applications of Ribavirin. New York, Academic Press , 1984, 203-209.

20.

Mustafa MM , Weitman SD , Winick NJ , et al: Subacute measles encephalitis in the young immunocompromised host: Report of two cases diagnosed by polymerase chain reaction and treated with ribavirin and review of the literature. Clin Infect Dis 1992; 16:654-660.

21.

ICN Pharmaceuticals : Investigational Drug Brochure, Intravenous Ribavirin. Basingstoke, UK, ICN Pharmaceuticals Inc, December 1998. IND #9,076.

22.

Crumpacker C. , Bubley G. , Lucey D. , et al: Ribavirin enters cerebrospinal fluid . Lancet 1986;ii:45-46.

23.

Hosoya M. , Shigeta S. , Mori S. , et al: High-dose intravenous ribavirin therapy for subacute sclerosing panencephalitis. Antimicrob Agents Chemother 2001;45:943-945.

24.

Solomon T. : Subacute sclerosing panencephalitis, in Gilman S , Goldstein GW , Waxman SG (eds): Neurobase, 4th 2002 ed. San Diego, Medlink Publishing, 2002 .